Kopran Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
KOPRAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kopran Limited's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified (clean) opinion from statutory auditor Khandelwal Jain & Co. Consolidated revenue from operations rose marginally to Rs. 629.60 crore from Rs. 614.59 crore, but profit after tax fell sharply to Rs. 38.55 crore from Rs. 50.96 crore (down ~24%). Standalone revenue declined ~20% to Rs. 271.01 crore and standalone PAT fell ~22% to Rs. 26.86 crore, indicating margin pressure at the parent level. The board recommended a dividend of Rs. 3.00 per share (30%), subject to shareholder approval at the upcoming AGM. A previously announced scheme to merge Kopran Laboratories Limited into Kopran Limited remains pending regulatory and shareholder approvals and is not yet reflected in these numbers.
Shareholders get a steady 30% dividend despite weaker earnings, offering some income support, but the sharp profit decline and rising short-term borrowings (up ~59% on a consolidated basis) signal working capital stress that could weigh on sentiment.